Jakarta, Indonesia – January 27, 2021 – Kalbe Genexine Biologics (“KGBio” or “the Company”), a leading integrate biologics holding company focused on the in-licensing, clinical development, and manufacturing of novel biologicals and biosimilar molecules, today announced that General Atlantic, a leading global growth equity firm, will invest US$55 million in primary capital in the Company. The investment will support KGBio's ongoing clinical development and commercialization needs, asset acquisition plan, and production capacity expansion efforts.